Allarity Therapeutics, Inc. (ALLR)
Chart Events
Performance Outlook
| Previous Close | 0.2500 |
| Open | 0.2458 |
| Bid | 0.2475 x 1000 |
| Ask | 0.2498 x 800 |
| Day's Range | 0.2370 - 0.2528 |
| 52 Week Range | 0.2000 - 9.6700 |
| Volume | |
| Avg. Volume | 2,105,711 |
| Market Cap | 1.999M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today announced that the Company’s 2023 Annual Meeting of Stockholders (the “Meeting”), on January 19, 2023, at 1:00 p.m. (Eastern Time) was adjourned without any business being conducted. The Meeting was adjourned until Frid
- GlobeNewswire
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the Company’s adjourned 2022 Annual Stockholders Meeting (“2022 ASM”) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (“2023 ASM”) will be held, as
- GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity’s cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expense
